[Skip to Content]
[Skip to Content Landing]
Editorial
April 2018

Tissue Markers for Acute Multiple Sclerosis Treatment Response—A Step Toward Personalized Medicine

Author Affiliations
  • 1Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
JAMA Neurol. 2018;75(4):406-407. doi:10.1001/jamaneurol.2017.4850

Personalized medicine is a medical model where treatment decisions are tailored to the patient in accordance with the specific characteristics of the individual and their disease. Typically, these decisions are based on the predicted treatment response of the patient, which is based on individual disease features. At present, treatment of multiple sclerosis (MS) relapses is far from personalized medicine: most patients receive 1 or 2 courses of corticosteroids, with treatment of unresponsive relapses escalating to apheresis (either plasma exchange or immunoabsorption).1,2 Predictors of response to either corticosteroids or plasma exchange are limited.

×